TY - JOUR
T1 - Antibody-based immunotherapy of aciclovir resistant ocular herpes simplex virus infections
AU - Bauer, Dirk
AU - Keller, Jessica
AU - Alt, Mira
AU - Schubert, Axel
AU - Aufderhorst, Ulrich Wilhelm
AU - Palapys, Vivien
AU - Kasper, Maren
AU - Heilingloh, Christiane Silke
AU - Dittmer, Ulf
AU - Laffer, Björn
AU - Eis-Hübinger, Anna Maria
AU - Verjans, Georges M.
AU - Heiligenhaus, Arnd
AU - Roggendorf, Michael
AU - Krawczyk, Adalbert
N1 - Publisher Copyright:
© 2017 The Authors
PY - 2017/12
Y1 - 2017/12
N2 - The increasing incidence of aciclovir- (ACV) resistant strains in patients with ocular herpes simplex virus (HSV) infections is a major health problem in industrialized countries. In the present study, the humanized monoclonal antibody (mAb) hu2c targeting the HSV-1/2 glycoprotein B was examined for its efficacy towards ACV-resistant infections of the eye in the mouse model of acute retinal necrosis (ARN). BALB/c mice were infected by microinjection of an ACV-resistant clinical isolate into the anterior eye chamber to induce ARN and systemically treated with mAb hu2c at 24 h prior (pre-exposure prophylaxis) or at 24, 40, and 56 h after infection (post-exposure immunotherapy). Mock treated controls and ACV-treated mice showed pronounced retinal damage. Mice treated with mAb hu2c were almost completely protected from developing ARN. In conclusion, mAb hu2c may become a reliable therapeutic option for drug/ACV-resistant ocular HSV infections in humans in order to prevent blindness.
AB - The increasing incidence of aciclovir- (ACV) resistant strains in patients with ocular herpes simplex virus (HSV) infections is a major health problem in industrialized countries. In the present study, the humanized monoclonal antibody (mAb) hu2c targeting the HSV-1/2 glycoprotein B was examined for its efficacy towards ACV-resistant infections of the eye in the mouse model of acute retinal necrosis (ARN). BALB/c mice were infected by microinjection of an ACV-resistant clinical isolate into the anterior eye chamber to induce ARN and systemically treated with mAb hu2c at 24 h prior (pre-exposure prophylaxis) or at 24, 40, and 56 h after infection (post-exposure immunotherapy). Mock treated controls and ACV-treated mice showed pronounced retinal damage. Mice treated with mAb hu2c were almost completely protected from developing ARN. In conclusion, mAb hu2c may become a reliable therapeutic option for drug/ACV-resistant ocular HSV infections in humans in order to prevent blindness.
KW - ARN
KW - Aciclovir resistance
KW - HSV
KW - Humanized Anti-HSV-antibody
KW - Infection of the eye
UR - http://www.scopus.com/inward/record.url?scp=85030309099&partnerID=8YFLogxK
U2 - 10.1016/j.virol.2017.09.021
DO - 10.1016/j.virol.2017.09.021
M3 - Article
C2 - 28985573
AN - SCOPUS:85030309099
SN - 0042-6822
VL - 512
SP - 194
EP - 200
JO - Virology
JF - Virology
ER -